Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preoperative erythropoietin and Ferinject for reducing transfusion after cardiac surgery
IRCT20221021056256N1Phase 3Completed
- Sponsor
- Shahid Beheshti University of Medical Sciences
- Start
- Nov 2022
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ferric carboxymaltose and erythropoietin in anaemia and Bleeding (2 arms), sponsored by Shahid Beheshti University of Medical Sciences. Primary endpoints: Blood consumption after heart surgery and Transfusion rate after cardiac surgery. Started Nov 2022; status: completed.
02
Drugs
ferric carboxymaltoseerythropoietin
03
Conditions
anaemiaBleeding
Beyond the preview
Go deeper on IRCT20221021056256N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20221021056256N1.